KP2032

KP2032 is a small molecule drug candidate being developed by K Pharma, Inc. for the treatment of Huntington's Disease (HD). Identified through an iPSC-based drug repositioning platform developed at Keio University, KP2032 is an existing approved drug being repurposed for its potential neuroprotective effects in HD. The program is currently in the preparation phase for Phase 1/2 clinical trials. The specific identity of the repositioned compound has not been widely disclosed in public pipeline summaries, but it was selected based on its ability to mitigate disease phenotypes in patient-derived neural cells, aiming to address the progressive neurodegeneration characteristic of the disease.